Homozygous Tangier disease and cardiovascular disease

Fredrickson, 1961, Tangier disease: combined clinical staff conference at the National Institutes of Health, Ann. Intern. Med., 55, 1016, 10.7326/0003-4819-55-6-1016 Fredrickson, 1964, The inheritance of high density lipoprotein deficiency (Tangier disease), J. Clin. Invest., 43, 228, 10.1172/JCI104907 Hoffman, 1965, Tangier disease (familial high density lipoprotein deficiency); clinical and genetic features in two adults, Am. J. Med., 39, 582, 10.1016/0002-9343(65)90081-1 Kocen, 1967, Familial alpha-lipoprotein deficiency (Tangier disease) with neurological abnormalities, Lancet, 1, 1341, 10.1016/S0140-6736(67)91759-X Engel, 1967, Neuropathy in Tangier disease: alpha-lipoprotein deficiency manifesting as familial recurrent neuropathy and intestinal lipid storage, Arch. Neurol., 17, 1, 10.1001/archneur.1967.00470250005001 Kummer, 1968, Familiare analphalipoproteinamie (TangierKrankeit), Schweiz. Med. Wochenschr, 98, 406 Kracht, 1970, Hypoalphalipoproteinamie (Tangier disease), Verh. Dtsch. Ges. Pathol., 54, 355 Haas, 1974, Tangier disease, Brain, 97, 351, 10.1093/brain/97.1.351 Bale, 1971, Pathology of Tangier disease, J. Clin. Pathol., 24, 609, 10.1136/jcp.24.7.609 Lindeskog, 1972, Serum lipoprotein deficiency in diffuse “normolipemic” plane xanthomas, Arch. Dermatol., 106, 529, 10.1001/archderm.106.4.529 Greten, 1974, Lipoproteins and lipolytic plasma enzymes in a case of Tangier disease, N. Engl. J. Med., 291, 548, 10.1056/NEJM197409122911103 Stanios, 1974, Cholesterolosis with alpha-lipoprotein deficiency (Tangier disease), Wiad Lek., 27, 205 Fetrans, 1975, The pathology of Tangier disease: a light and electron microscopic study, Am. J. Pathol., 78, 101 Utermann, 1975, Plasma lipoprotein abnormalities in a case of primary highdensity-lipoprotein (HDL) deficiency, Clin. Genet., 8, 258, 10.1111/j.1399-0004.1975.tb01501.x Assman, 1976, Tangier krankeit, 460 Brook, 1977, Tangier disease (alpha-lipoprotein deficiency), J. Am. Med. Assoc., 238, 332, 10.1001/jama.238.4.332 Herbert, 1978, Familial lipoprotein deficiency (abetalipoproteinemia, hypobetalipoproteinemia and Tangier disease), 488 Dyck, 1978, Adult-onset of Tangier disease. 1. Morphometric and pathologic studies suggesting delayed degradation of neu tral lipids after fiber degeneration, J. Neuropathol. Exp. Neurol., 37, 119, 10.1097/00005072-197803000-00002 Suarez, 1982, Tangier disease: heterozygote detection and linkage analysis, Hum. Genet., 60, 150, 10.1007/BF00569702 Frith, 1982, Tangier disease with normal serum cholesterol, Aust. N.Z. J. Med., 12, 515, 10.1111/j.1445-5994.1982.tb03834.x Dechelotte, 1984, La maladie de Tangier, Arch. Anat. Cytol. Pathol., 32, 376 Ohtaki, 1983, A Japanese family with high density lipoprotein deficiency, Atherosclerosis, 49, 79, 10.1016/0021-9150(83)90009-6 Vergani, 1984, Bile lipid composition and haemostatic variables in a case of high density lipoprotein deficiency (Tangier disease), Eur. J. Clin. Invest., 14, 49, 10.1111/j.1365-2362.1984.tb00703.x Tarao, 1984, Japanese adult siblings with Tangier disease and statistical analysis of reported cases, Tokai. J. Exp. Clin. Med., 9, 379 Gibbels, 1985, Severe polyneuropathy in Tangier disease mimicking syringomyelia or leprosy: clini cal, biochemical, electrophysiological, and morphological evaluation including electron microscopy of nerve, muscle, and skin biopsies, J. Neurol., 232, 283, 10.1007/BF00313867 Pietrini, 1985, Neuropathy in Tangier disease: a clinicopathologic study and a review of the literature, Acta Neurol. Scand., 72, 495, 10.1111/j.1600-0404.1985.tb00907.x Clerc, 1986, Analphalipoproteinemie et risque cardiovasculaire. Cas de la maladie de Tangier, Bull. Acad. Natl. Med., 170, 141 Pressly, 1987, Cardiac valvular involvement in Tangier disease, Am. Heart J., 113, 200, 10.1016/0002-8703(87)90032-9 Schmalbruch, 1987, Abnormalities in spinal neurons and dorsal root ganglion cells in Tangier disease presenting with syringomyelia-like syndrome, J. Neuropathol. Exp. Neurol., 46, 533, 10.1097/00005072-198709000-00003 Frohlich, 1987, Interaction of high density lipoprotein with adipocytes in a new patient with Tangier disease, Clin. Inv. Med., 10, 377 Bracco, 1988, Familial high density lipoprotein deficiency (Tangier disease): the third Italian case, J. Inher. Metab. Dis., 11, 155, 10.1007/BF01804223 Reinhard, 1989, Haemolytic anaemia in analpha-lipoproteinaemia (Tangier disease): morphological, biochemical, and bio physical properties of the red blood cells, Br. J. Haematol., 72, 272, 10.1111/j.1365-2141.1989.tb07694.x Leal Luna, 1989, Tangier disease: study of the first case in Spain, Med. Clin., 93, 301 Lo, 1990, Tangier disease in a black patient: an unusual clinical presentation, Am. J. Med., 89, 105, 10.1016/0002-9343(90)90108-P Kunitake, 1990, Conformation of apolipoprotein B-100 in the low density lipoproteins of Tangier disease; identification of localized conformational response to triglyceride content, J. Biol. Chem., 265, 20739, 10.1016/S0021-9258(17)45278-1 Schmitz, 1990, Dysregulation of lipid metabolism in Tangier monocyte-derived macrophages, Arteriosclerosis, 10, 1010, 10.1161/01.ATV.10.6.1010 Schaefer, 1980, Coronary heart disease prevalence and other clinical features in familial high density lipoprotein defi ciency (Tangier disease), Ann. Intern. Med., 93, 261, 10.7326/0003-4819-93-2-261 The Expert Panel, 1993, Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel (ATP II) on detection, evaluation and treatment of high blood cholesterol in adults, J. Am. Med. Assoc., 269, 3015, 10.1001/jama.269.23.3015 Anderson, 1991, An updated coronary risk profile. A statement for health professionals, AHA medical/scientific statement science advisory, Circulation, 83, 356, 10.1161/01.CIR.83.1.356 Schaefer, 1978, Plasmatriglycerides in regulation of HDL-cholesterol levels, Lancet, 2, 391, 10.1016/S0140-6736(78)91863-9 Schaefer, 1986, Metabolism of the apolipoproteins A-I, A-II, and A-IV, Methods Enzymol., 129, 420, 10.1016/0076-6879(86)29083-7 Schaefer, 1982, Human apolipoprotein A-I and A-II metabolism, J. Lipid Res., 23, 850, 10.1016/S0022-2275(20)38087-1 Brinton, 1991, Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein cholesterol levels with or without hypertriglyceridemia, J. Clin. Invest., 87, 536, 10.1172/JCI115028 Le, 1988, Heterogeneity of apolipoprotein A-I turnover with reduced concentrations of plasma high density lipoprotein cholesterol, Metabolism, 37, 614, 10.1016/0026-0495(88)90077-7 Genest, 1991, Prevalence of risk factors in men with premature coronary artery disease, Am. J. Cardiol., 67, 1185, 10.1016/0002-9149(91)90924-A Genest, 1992, Prevalence of lipoprotein cholesterol and apolipoprotein A-I, B and Lp(a) abnormalities in men with premature coronary artery disease, Am. Coll. Cardiol., 19, 792, 10.1016/0735-1097(92)90520-W Genest, 1992, Prevalence of familial lipoprotein disorders in patients with premature coronary artery disease, Circulation, 85, 2025, 10.1161/01.CIR.85.6.2025 Schaefer, 1984, The clinical, biochemical, and genetic features in familial disorders of high density lipoprotein deficiency, Arteriosclerosis, 4, 303, 10.1161/01.ATV.4.4.303 Schaefer, 1982, Plasma apolipoprotein A-I absence associated with marked reduction of high density lipoproteins and premature coronary artery disease, Arteriosclerosis, 2, 16, 10.1161/01.ATV.2.1.16 Schaefer, 1985, Familial apolipoprotein A-I and C-III deficiency, variant II, J. Lipid Res., 26, 1089, 10.1016/S0022-2275(20)34282-6 Ordovas, 1989, Familial apolipoprotein A-1, C-111, and A-IV deficiency with marked high density lipoprotein deficiency and premature atherosclerosis due to a deletion of the apolipoprotein A-I, C-111, and A-IV gene complex, J. Biol. Chem., 264, 16339, 10.1016/S0021-9258(19)84708-7 Norum, 1982, Familial deficiency of apolipoproteins A-I and C-111 and precocious coronary artery disease, N. Engl. J. Med., 306, 1513, 10.1056/NEJM198206243062503 Norum, 1986, Clinical syndrome and lipid metabolism in hereditary deficiency of apolipoproteins A-I and C-III, variant I, Adv. Exp. Med. Biol., 201, 137 Karathanasis, 1987, DNA inversion within the apolipoprotein A-I/C-III/A-IV encoding gene cluster of certain patients with premature atherosclerosis, 84, 7198 Matsunaga, 1991, Apolipoprotein A-I deficiency due to a codon 84 nonsense mutation of the apolipoprotein A-I gene, 88, 2793 Deeb, 1991, A mutation in the human apolipoprotein A-I gene. Dominant effect on the level and characteristics of plasma high density lipoproteins, J. Biol. Chem., 266, 13654, 10.1016/S0021-9258(18)92750-X Funke, 1991, A frameshift. mutation in the human apolipoprotem A-I gene causes high density lipoprotein deficiency, partial lecithin:cholesterol acyltrasferase deficiency, and corneal opacities, J. Clin. Invest., 87, 371, 10.1172/JCI114997 von Eckardstein, 1990, Structural analysis of human apolipoprotein A-I variants. Amino acid substitutions are nonrandomly distributed throughout the apolipoprotein A-I primary structure, J. Biol. Chem., 265, 8610, 10.1016/S0021-9258(19)38931-8 von Eckardstein, 1989, Apolipoprotein A-I variants. Naturally occurring substitutions of proline resi dues affect plasma concentration of apolipoprotein A-I, J. Clin. Invest., 84, 1722, 10.1172/JCI114355 Ladias, 1990, Apolipoprotein A-I Baltimore (Arg10-Leu), a new apo A-I variant, Hum. Genet., 84, 439, 10.1007/BF00195816 Strobl, 1988, Apolipoprotein A-I (Glu 198-Lys): a mutant of the major apolipoprotein of highdensity lipoproteins occurring in a family with dyslipoproteinemia, Pediatr. Res., 24, 222, 10.1203/00006450-198808000-00017 Glomset, 1983, Familial lecithin:cholesterol acyltransferase deficiency, 643 Carlson, 1982, Fish-eye disease: a new familial condition with massive corneal opacities and dyslipoproteinemia, Eur. J Clin. Invest., 12, 41, 10.1111/j.1365-2362.1982.tb00938.x Carlson, 1985, Evidence for deficiency of high density lipoprotein lecithin:cholesterol acyltransferase activity (LCAT) in fish eye disease, Acta Med. Scand., 218, 189, 10.1111/j.0954-6820.1985.tb08846.x Weisgraber, 1980, A–I Milano apoprotein: Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins, J. Clin. Invest., 66, 901, 10.1172/JCI109957 Schaefer, 1978, Metabolism of high density lipoprotein apolipoproteins in Tangier Disease, N. Engl. J. Med., 299, 905, 10.1056/NEJM197810262991701 Schaefer, 1981, Metabolism of high density lipoprotein subfractions and constituents in Tangier Disease following the infusion of high density lipoproteins, J. Lipid Res., 22, 217, 10.1016/S0022-2275(20)35365-7 Alaupovic, 1981, Plasma apolipoprotein concentrations in familial apolipoprotein A-1 and A-II deficiency (Tangier Disease), Metabolism, 30, 805, 10.1016/0026-0495(81)90027-5 Makrides, 1988, Sequence and expression of Tangier apo A-I gene, Eur. Biochem., 173, 465, 10.1111/j.1432-1033.1988.tb14022.x Schaefer, 1983, Massive omental reticuloendothelial cell lipid uptake in Tangier Disease following splenectomy, Am. J. Med., 75, 521, 10.1016/0002-9343(83)90359-5 Chu, 1979, Ocular manifestations of familial high density lipoprotein deficiency (Tangier Disease), Arch. Opthamol., 97, 1926, 10.1001/archopht.1979.01020020374020 Gordon, 1986, High density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial, Circulation, 74, 1217, 10.1161/01.CIR.74.6.1217 Frick, 1987, Helsinki Heart Study: a primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease, N. Engl. J. Med., 317, 1237, 10.1056/NEJM198711123172001 Manninen, 1988, Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study, J. Am. Med. Assoc., 260, 641, 10.1001/jama.260.5.641 Manninen, 1992, Joint effects of serum triglyceride and LPL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment, Circulation, 85, 37, 10.1161/01.CIR.85.1.37 Brown, 1990, Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B, N. Engl. J. Med., 323, 1289, 10.1056/NEJM199011083231901 Blankenhorn, 1987, Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts, J. Am. Med. Assoc., 257, 3233, 10.1001/jama.257.23.3233